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Abstract
Psidium guajava Linn. (guava) is used not only as food but also as folk medicine in subtropical areas around the
world because of its pharmacologic activities. In particular, the leaf extract of guava has traditionally been used for
the treatment of diabetes in East Asia and other countries. Moreover, the anti-hyperglycemic activity of the extract
has been reported in some animal models. However, little is known regarding the therapeutic activity of the
extract in human clinical trials as well as its underlying therapeutic mechanisms and safety. In Japan, Guava Leaf
Tea (Bansoureicha®, Yakult Honsha, Tokyo, Japan) containing the aqueous leaf extract from guava has been
approved as one of the Foods for Specified Health Uses and is now commercially available. This review describes
the active component of the aqueous guava leaf extract and its inhibition of alpha-glucosidase enzymes in vitro,
safety of the extract and Guava Leaf Tea, reduction of postprandial blood glucose elevation, and improvement of
hyperglycemia, hyperinsulinemia, hypoadiponectinemia, hypertriglycemia and hypercholesterolemia in murine
models and several clinical trials. It is suggested that the chronic suppression of postprandial blood glucose eleva-
tion is important in preventing type 2 diabetes mellitus, and that Guava Leaf Tea is considered useful as an alimen-
totherapy for chronic treatment.
Background
The number of diabetes mellitus (DM) cases has been
increasing worldwide in recent years. In 2000, the
World Health Organization estimated a total of 171 mil-
lion (2.8%) people with DM from the global population,
and this figure has been projected to increase to 366
million (4.4%) by 2030 [1]. In particular, cases of type 2
DM (T2DM) have been increasing in contrast to cases
of type 1 DM (T1DM), an autoimmune disease resulting
in the destruction of insulin-producing beta cells of the
pancreas and the failure to produce insulin. In more
developed countries, the cure and prevention of T2DM
have become important concerns. On the other hand,
T2DM is expected to become a more serious problem
in developing countries because of the trend of urbani-
zation and consequent lifestyle changes, perhaps most
importantly exemplified by a shift to the “Western-style”
diet, which is high in fat.
T2DM is generally characterized by hyperglycemia,
insulin resistance (reduced insulin sensitivity) and obe-
sity. Obesity is associated with not only T2DM but also
hyperlipidemia and hypertension. Coexistence of these
diseases is well known as metabolic syndrome, a high
risk factor for cardiovascular disease [2-4]. Insulin resis-
tance is considered a key feature of these diseases and is
defined as a state requiring more insulin in order to
obtain the biological effects achieved with a lower insu-
lin level in the normal state. This metabolic abnormality
is induced by obesity, especially increased visceral fat,
via the enhancement of inflammation and hypoadipo-
nectinemia. Adiponectin is an adipocytokine specifically
and abundantly expressed in adipose tissue which
directly sensitizes to insulin, and its level is inversely
correlated to the percentage of body fat in adults. Treat-
ment with thiazolidine derivatives, one type of anti-dia-
betic drugs, ameliorates insulin resistance and increases
serum adiponectin level in T2DM patients with hypoa-
diponectinemia [5]. Therefore, improvement of insulin
resistance and hypoadiponectinemia is expected to be
an effective therapeutic strategy for the improvement
and/or prevention of T2DM as well as metabolic
syndrome.
The common guava tree (Psidium guajava Linn.) is a
member of the Myrtaceae family, which is native to tro-
pical and subtropical countries. Its fruit is commonly
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common use of Psidium guajava Linn. (guava) is as folk
medicine. Aside from these uses, Gutiérrez et al. [6]
have reviewed the potential pharmacologic activities of
the extract from the fruit, leaf, bark or roots; these activ-
ities include antioxidant, hepatoprotective, anti-allergy,
anti-microbial, anti-genotoxic, anti-plasmodial, cytotoxic,
anti-spasmodic, cardioactive, anti-cough, anti-diabetic,
anti-inflammatory and anti-nociceptive activities in vitro
and/or in animal models. Interestingly, guava leaves
have also attracted attention as a folk remedy for dia-
betes not only in Japan and East Asia [7-9] but also in
Africa [10]. However, little is known regarding the anti-
hyperglycemic or anti-diabetic activity of the guava leaf
extract in clinical trials, except for traditional uses [8]
and the effects of a single ingestion of guava juice in
healthy volunteers and a few diabetic subjects [11].
Moreover, its underlying therapeutic mechanisms and
safety in terms of interaction with other medicines
remain unclarified.
For the maintenance and promotion of health and the
prevention of lifestyle associated disease, the Japanese
Ministry of Health, Labor and Welfare first published
“Foods for Specified Health Uses” (FOSHU). FOSHU
lists foods whose claims of their physiological effects on
the human body have been officially approved and such
foods were legally permitted to be used as dietary pro-
ducts for health preservation [12]. Guava Leaf Tea (Ban-
soureicha®, Yakult Honsha, Tokyo, Japan), which
contains the aqueous guava leaf extract (GvEx), has
been approved as FOSHU and recommended for sub-
jects with pre-diabetes; it is presently commercially
available in Japan [13].
This article reviews evidence regarding the anti-hyper-
glycemic activities and safety of GvEx and Guava Leaf
T e ai nv i t r o ,a sw e l la si na n i m a lm o d e l sa n ds e v e r a l
clinical trials. It also describes the efficacy and safety of
Guava Leaf Tea in pre-diabetic and diabetic patients
with T2DM.
Review
1. Inhibition of alpha-glucosidase enzymes by GvEx and
its active component
In the digestive tract, some alpha-glucosidase enzymes,
such as alpha-amylase, maltase and sucrase, digest car-
bohydrates to glucose that can be absorbed through the
intestine. Alpha-glucosidase inhibitors (alpha-GIs),
namely, acarbose and voglibose, prevent the digestion of
carbohydrates based on competitive enzyme inhibition,
and provide short-term glycemic control [14].
Deguchi et al. [15] demonstrated that GvEx, which
was prepared by hot water extraction from guava leaves,
inhibited the in vitro activities of maltase, sucrase, and
alpha-amylase in a dose-dependent manner (Fig. 1). The
50% inhibitory concentration (IC50) of GvEx was 0.6
mg/mL for alpha-amylase, 2.1 mg/mL for maltase, and
3.6 mg/mL for sucrase, indicating the higher inhibitory
activity of alpha-amylase than the other two enzymes.
Furthermore, Wang et al. [16] found that the aqueous
extract from guava leaves inhibited both sucrase and
maltase activities in the small intestinal mucosa of dia-
betic mice, occurring as a mixed type of competitive
and non-competitive inhibition.
In order to clarify the active component of the guava
leaf extract, GvEx solution was fractionated in dialysis
tubes of 5,000 and 30,000 MW pore size. The inhibitory
activity of alpha-amylase was detected in the fraction
with a MW between 5,000 and 30,000. This fraction
reacted with ferrous tartrate, indicating that a compo-
nent with a phenolic hydroxyl group was part of the
fraction [17]. It has been reported that guava leaf con-
tains some polyphenols, such as peduncladgin, casuari-
nin and isostrictinin [18-20]. However, high-
performance liquid chromatography (HPLC) analysis
demonstrated that these elementary polyphenols were
present in the ethyl acetate extract of guava leaf but not
in GvEx. Several instrumental analyses, such as
1H-
nuclear magnetic resonance (NMR), infrared absorption
spectrum, and solid
13C-NMR, have suggested that the
active component of GvEx was a polymerized polyphe-
nol named guava leaf polyphenol (GvPP), which is
Figure 1 Dose-dependent inhibition of alpha-amylase, maltase
and sucrase by GvEx. Enzyme reaction was conducted for the
specified time, and the amount of glucose or maltose produced
was measured by HPLC. Maltase and sucrase derived from acetone
powder of rat intestine, and alpha-amylase obtained from porcine
pancreas were purchased from Sigma Chemical Co. (St. Louis, MO,
USA) [15].
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cular-weight polyphenols [17].
Here, it was shown that the GvEx acts as an alpha-GI
in vitro and contains GvPP as the active component.
2. Reduction of postprandial blood glucose elevation
2.1 Murine models
It is well known that orally administered alpha-GIs have
the potential to reduce postprandial blood glucose eleva-
tion as shown in a carbohydrate loading test in vivo
[21-24]. To determine the effect of GvEx on postpran-
dial blood glucose elevation, normal mice were immedi-
ately given GvEx or saline (control) following overnight
fasting. Thirty minutes later, soluble starch, sucrose or
maltose (2 g/kg) was loaded and blood glucose level was
measured at 30-min intervals from 0 to 120 min. Com-
pared with control, the single ingestion of GvEx signifi-
cantly reduced the area under the curve (AUC) of
postprandial blood glucose levels by 37.8% after loading
soluble starch at 250 mg/kg and by 31.0% and 29.6%
after loading sucrose and maltose, respectively at 500
mg/kg each [15]. Additionally, in streptozotocin-induced
diabetic mice with a fasting blood glucose (FBG) level of
>200 mg/dL, which is a model of T1DM, the single
ingestion of GvEx (250 mg/kg) significantly reduced the
AUC after loading soluble starch (unpublished data).
Furthermore, anti-hyperglycemic activity was detected in
animal models with T1DM [10,25,26].
2.2 Human trials with normal, pre-diabetic and type 2
diabetic subjects
According to the preparation method of GvEx, Guava
Leaf Tea was manufactured for human trial. To clarify
the above-mentioned findings in animal models, a cross-
over study was designed to evaluate the effects of a sin-
gle ingestion of Guava Leaf Tea on postprandial blood
glucose elevation in normal and pre-diabetic subjects
[15]. The single ingestion of Guava Leaf Tea signifi-
cantly reduced postprandial blood glucose elevation at
30, 90 and 120 min (Fig. 2a). In addition, the AUC of
the glucose level after carbohydrate loading (ingestion of
cooked rice) was significantly reduced by about 20%
compared with control (Fig. 2b).
A crossover clinical trial involving 20 hospitalized
patients with T2DM was conducted to compare the
potential of Guava Leaf Tea and voglibose (Basen®;
Takeda Chemical Industries, Ltd., Tokyo, Japan) to
reduce postprandial blood glucose elevation [27]. As
shown in Figure 3, the postprandial glucose level 2 hours
after meal was elevated to ca. 160 mg/dL in the patients
with each standard treatment (in control). The elevated
level was significantly reduced with the single administra-
tion of Guava Leaf Tea and voglibose to 143 mg/dL (p <
0.001) and 133 mg/dL (p < 0.001), respectively. The redu-
cing potential was significantly milder with Guava Leaf
Tea than with voglibose (p < 0.01). There were no side
effects, such as hypoglycaemia, due to abnormal interac-
tion in the combined administration of each standard
treatment and voglibose or Guava Leaf Tea [27].
Taken together, these findings, suggest that the single
ingestion of GvEx or Guava Leaf Tea can reduce post-
prandial glucose elevation via the inhibition of alpha-
glucosidase in mice and human subjects with or without
diabetes. Furthermore, Guava Leaf Tea was found to
have milder activity than voglibose.
3. Improvement of diabetes symptoms and
hyperlipidemia
3.1 Diabetic animal models
In previous studies, patients with T2DM were treated
with alpha-GIs, namely, acarbose [23] or voglibose [24]
because long-term oral administration has been reported
to improve diabetic markers [e.g., hemoglobin A1c
(HbA1c) and insulin resistance]. Deguchi et al. [15] pre-
viously examined the effects of consecutive ingestion of
GvEx for 7 weeks on the progression of T2DM and
nephropathy in genetically diabetic mouse models (i.e.,
C57BL/Ksj, db/db, and Lepr
db/Lepr
db). They showed
that the mice developed widespread pathological
abnormalities including not only diabetes and obesity
but also well-defined nephropathy [28,29]. Compared
with drinking water (control), the GvEx (250 mg/kg/
day) solution significantly reduced blood HbA1c%a f t e r
ingestion for 5 and 7 weeks. GvEx also improved
nephropathy with a significant reduction in the thicken-
ing index of the glomerular mesangial matrix in the kid-
ney observed at 7 weeks (Table 1). In contrast, there
were no significant effects on weight gain, food and
water intakes of the diabetic mice.
Recently, Shen et al.[30] have reported the effects of
the aqueous extract from guava leaves on type 2 diabetic
rats. They showed that long-term feeding of the extract
significantly reduced blood glucose level, increased
plasma insulin level in an oral glucose tolerance test,
and stimulated activities of some glucose metabolic
enzymes. Additionally, the single feeding of the extract
significantly reduced blood glucose level in an oral glu-
cose tolerance test. However, the underlying mechan-
isms have not yet been clearly elucidated.
The above-mentioned findings indicate that the conse-
cutive ingestion of GvEx has the potential to improve
diabetes symptoms such as hyperglycemia, nephropathy
and insulin resistance in diabetic animal models.
3.2 Human trials in pre-diabetic and type 2 diabetic
patients
To confirm previous findings in diabetic animal models,
a first long-term clinical trial was conducted to evaluate
the effects of consecutive ingestion of Guava Leaf Tea
with every meal for 12 weeks on the parameters of dia-
betes symptoms and safety in 15 male subjects with pre-
diabetes and mild type 2 diabetes [31].
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analysis results between the initial week and week 12 of
ingestion of Guava Leaf Tea in subjects with pre-dia-
betes and mild diabetes. In all the subjects, the FBG
level showed a decrease from 136 to 131 mg/dL (p =
0.07) and a significant reduction was detected after the
calculation of reduction rate of the FBG level. In parti-
cular, the FBG level showed a more pronounced
decrease in the pre-diabetic subjects (p = 0.06; n = 7;
initial FBG level: 110-126 mg/dL). Five of seven pre-dia-
betic subjects showed a reduction in blood HbA1c%.
Also, the levels of insulin, C-peptide and homeostasis
model assessment for insulin resistance (HOMA-IR) sig-
nificantly decreased in all subjects. Moreover, after the
ingestion of Guava Leaf Tea for 12 weeks, serum levels
of total cholesterol (T-CHO) and triglyceride (TG)
Figure 2 Effect of single ingestion of Guava Leaf Tea on postprandial blood glucose elevation in human subjects.( a )T i m ec o u r s eo f
changes in blood glucose level. (b) Area under the curve in changes in blood glucose level. Nineteen subjects aged over 40 years, with or
without pre-diabetes, with an FBG level of 103.0 ± 14.3 mg/dL and a body mass index (BMI) of >22.0 were recruited. After overnight fasting for
11 hours, the subjects ingested 200 g of cooked rice as a loading carbohydrate together with a bottle (190 mL) of hot water at week 1 and
then with the same volume of Guava Leaf Tea containing about 400 mg of GvEx at week 2. Blood glucose level was measured at 30-min
intervals for up to 150 min after ingestion. *: p < 0.05, **: p < 0.01 (paired t-test) [15].
Figure 3 Effects of Guava Leaf Tea and voglibose on postprandial blood glucose elevation in patients with T2DM.T h r e ed a y sb e f o r e
and during the trial period, all patients with T2DM were treated with their usual anti-diabetic medication, namely, insulin, sulfonylurea and/or
biguanide except for alpha-GI, followed by dietary treatment and/or exercise to control the FBG level at approximately 100 mg/dL. The subjects
were randomized to group A or B and received their usual treatment only on day 1 (control). On day 2, the subjects in groups A and B were
administered Guava Leaf Tea (200 ml) with meal and voglibose (3 mg) before meal, respectively. On day 3, the subjects were crossed-over for
the administration of other treatment. The FBG and postprandial blood glucose levels were assayed before and 2 hours after meal, respectively.
The combined data was analyzed using the Tukey test. **: p < 0.01, ***: p < 0.001 [27].
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terolemia and hypertriglycemia (n = 7 and n = 5; initial
levels: >220 mg/dL and >150 mg/dL, respectively).
There were no abnormal changes in the parameters of
iron metabolism, liver and kidney functions, blood
chemistry and on items covered in the physician’s physi-
cal examination and health interviews during this trial
[31].
A second long-term clinical trial investigated the
effects of consecutive ingestion of Guava Leaf Tea for 8
weeks on the parameters of diabetes symptoms and
safety in diabetic patients receiving therapy, that is, anti-
diabetic medication with or without an inhibitor of
HMG-CoA reductase [32].
Table 2 shows the serum parameters of diabetes and
analysis results between the initial week and week 8 of
ingestion of Guava Leaf Tea in diabetic patients with
some medication. Ingestion of the tea significantly
decreased blood HbA1c% in diabetic patients who had
initial values of >6.5% and were assessed to have abnor-
mal control of blood glucose level. Additionally, the
ingestion of the tea significantly reduced serum insulin
level in diabetic patients with hyperinsulinemia whose
serum insulin level was >17 μU/ml before intake. The
ingestion of the tea also decreased the parameter values
of lipid metabolism, that is, triglycerides (TG; p < 0.05,
for 4 weeks), nonesterified fatty acids (NEFAs; p < 0.05,
for 4 weeks), remnant-like particle-cholesterol (p = 0.08,
for 4 weeks) and phospholipids (p = 0.06, for 8 weeks),
in the subjects with values higher than the reference
values in patients without fluvastatin treatment. In con-
trast, neither side effects resulting from alterations in
the parameter values of liver and kidney functions or
blood chemistry nor changes in doctor’s health inter-
views were observed during the entire clinical trial per-
i o d .A l s o ,t h e r ew a sn oh y p o g l y c e m i ad u et ot h e
abnormal interaction between Guava Leaf Tea and anti-
diabetic drugs with or without an HMG-CoA reductase
inhibitor [32].
Taken together, it is suggested that the consecutive
ingestion of Guava Leaf Tea with every meal improves
diabetes symptoms, such as hyperglycemia, hyperinsuli-
nemia, insulin resistance as well as hyperlipidemia in
pre-diabetic and mild diabetic patients with or without
hyperlipidemia. Moreover, it is indicated that the conse-
cutive ingestion of Guava Leaf Tea in addition to anti-
diabetic and anti-hypercholesterolemia medications
shows no side effects due to the abnormal interaction.
4. Improvement of hypercholesterolemia and
hypoadiponectinemia
To verify the anti-hyperlipidemic activity of Guava Leaf
Tea, a third long-term clinical trial investigated the
effects of consecutive intake for 8 weeks on the para-
meters of hyperlipidemia, diabetes and safety in 23 sub-
jects with borderline or mild hyperlipidemia with or
without T2DM. During the trial, 7 subjects were
Table 1 Effect of GvEx on glomeruli in db/db mice
Glomeruli
Group Number of thickened matrix
1)
Control (n = 10) 11.3 ± 2.7
GvEx (n = 9) 7.2 ± 2.6 **
Six-week-old db/db (C57BL/KsJ) mice were equally divided into 2 groups
according to body weight. All animals were permitted water or GvEx solution
(250 mg/kg bw/day) mixed in tap water and diet (MF commercial diet,
Oriental Yeast Co., Ltd., Tokyo, Japan) ad libitum. The study period was 7
weeks [15].
1) Number of glomeruli per specimen with moderate and marked changes.
Values are expressed as mean ± SD. **: p < 0.01 (Student’s t-test).
Table 2 Effect of consecutive ingestion of Guava Leaf Tea on serum parameters of carbohydrate metabolism in pre-
and mild diabetic patients and diabetic patients with T2DM under anti-diabetic medication
Serum parameter Pre- and mild diabetic patients
1) Type 2 diabetic patients
2)
n Initial week Week 12 n
3) Initial week Week 8
FBG (mg/dL) 15 136 ± 22 131 ± 25
#1 21 183 ± 71 171 ± 76
111-127 mg/dL 7 118 ± 7 112 ± 6
#2
Reduction rate of FBG (%) 15 0 4.3 ± 7.6*
HbA1c(%) 15 6.1 ± 0.7 6.2 ± 0.8 22 7.4 ± 1.4 7.4 ± 1.3
≧ 6.5% 15 8.1 ± 1.1 7.8 ± 1.1*
Insulin (μU/mL) 15 9.0 ± 3.0 7.0 ± 2.0** 19 28.7 ± 26.3 21.5 ± 18.0
≧ 17 μU/mL 11 43.6 ± 25.5 27.5 ± 19.4*
HOMA-IR 15 3.1 ± 1.3 2.3 ± 1.0** 19 12.2 ± 9.9 10.8 ± 13.0
1) Guava Leaf Tea (190 ml/bottle) was ingested 3 times/day with each meal for 12 weeks by pre-diabetic and mild type 2 diabetic subjects who were 15 males,
over 45 years of age and who had an FBG level of 110 mg/dL or higher and a BMI of >22.0.
2) Guava Leaf Tea (200 ml/bottle) was ingested 3 times/day with every meal for 8 weeks by 22 patients with T2DM who had a blood HbA1c% of >6.0% before
intake. Of these 22 patients, 19 received anti-diabetic medication (insulin, sulfonylurea and/or alpha-GI) throughout the trial. Three patients with
hypercholesterolemia were also administered fluvastatin, an inhibitor of HMG-CoA reductase in addition to an anti-diabetic drug throughout the trial.
3) Some data under the no fasting condition are omitted.
Values are expressed as mean ± SD. *: p < 0.05, **: p < 0.01,
#1: p = 0.07,
#2: p = 0.06 (Dunnett’s multiple paired test). Reproduced from [1532] with some
modifications.
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timide (an inhibitor of cholesterol absorption) or ethyl
icosapentate (a TG reducer) [33].
Table 3 shows the changes in serum lipid parameters
after the ingestion of Guava Leaf Tea for 8 weeks in
subjects with hypercholesterolemia (initial T-CHO level:
>220 mg/dL). The consecutive ingestion reduced the
serum levels of T-CHO (p < 0.05), LDL-cholesterol
(LDL-CHO) (p = 0.06) and phospholipid (p < 0.05) in
these subjects. A significant reduction in T-CHO level
(p < 0.05) was also observed in the same subjects receiv-
ing no medicinal treatment. On the other hand, the
levels of high-density lipoprotein cholesterol (HDL-
CHO), TG, NEFA and lipid peroxide were not signifi-
cantly changed in the same subjects. In contrast, the
consecutive ingestion decreased the serum level of TG
(p < 0.05, week 4) in subjects with hypertriglycemia
(initial TG level: >150 mg/dL) and that of phospholipid
(p < 0.05, weeks 4 and 8) in subjects with hyperpho-
spholipidemia (initial phospholipid level: >250 mg/dL).
Moreover, the ingestion of Guava Leaf Tea signifi-
cantly reduced blood HbA1c %i nd i a b e t i cs u b j e c t s
(initial HbA1c%: >6.5%), and significantly increased
serum adiponectin level in each subject with hypoadipo-
nectinemia (Table 4) and hyperglycemia. The nutritional
intake of all the subjects showed no significant variation
in the results of the questionnaires that were designed
for 1 week in the first, middle and last weeks of the trial
period [33]. This suggests that the trial findings were
due to the effects of ingestion of Guava Leaf Tea and
not from nutritional intake. There were no abnormal
changes in the parameters of liver and kidney function,
blood chemistry and doctor’s health interviews during
the entire trial period. Also, side effects such as hypogly-
cemia due to the abnormal interaction between Guava
Leaf Tea and an HMG-CoA reductase inhibitor,
colestimide (an inhibitor of cholesterol absorption) or
ethyl icosapentate [33] were not observed.
Overall, the results indicate that the consecutive inges-
tion of Guava Leaf Tea together with every meal
improves not only hyperglycemia but also hypoadipo-
nectinemia, hypercholesterolemia and hyperlipidemia in
pre-diabetic and diabetic patients with or without hyper-
lipidemia. The consecutive ingestion also ameliorates
high blood cholesterol level in subjects with hypercho-
lesterolemia or borderline hypercholesterolemia.
5. Safety
To confirm the safety of GvEx and Guava Leaf Tea, sev-
eral toxicity studies have been conducted in vitro, as
well as in animal models and human subjects.
In single-dose and 1-month repeated dose toxicity stu-
dies, Kobayashi et al. [34] demonstrated that the oral
administration of GvEx (200 and 2000 mg/kg/day)
caused no abnormal effects in rats, indicating that there
is neither acute nor chronic toxicity. Oyama et al. [35]
investigated the mutagenic activity of both GvEx and
Guava Leaf Tea. They found that Guava Leaf Tea had a
lower mutagenic activity than commercial green tea and
black tea in a DNA repair test (Rec-assay); however,
these teas showed no mutagenic activity in a bacterial
reverse mutation test (Ames test). Moreover, GvEx did
not induce chromosomal aberrations in a micronuclear
test using peripheral blood erythrocytes, which were
prepared from mice by a single oral administration of
GvEx (2000 mg/kg). From these findings, it is suggested
that Guava Leaf Tea and these commercial teas have no
genotoxicity.
After the approval as FOSHU, Guava Leaf Tea has
been taken by not only subjects with pre-diabetes but
also patients with mild and moderate T2DM. If the
ingested Guava Leaf Tea interacts with anti-diabetic and
Table 3 Effect of consecutive ingestion of Guava Leaf Tea
on serum lipid parameters in subjects with
hypercholesterolemia
Serum parameter n Initial week Week 8
T-CHO (mg/dL) 16 249 ± 20 235 ± 30q *
Without medical treatment 10 248 ± 21 231 ± 28*
LDL-CHO (mg/dL) 16 155 ± 23 143 ± 31
#
HDL-CHO (mg/dL) 16 54 ± 13 52 ± 13
TG (mg/dL) 16 212 ± 113 202 ± 105
NEFA (mEq/L) 14 0.62 ± 0.26 0.47 ± 0.25
Phospholipid (mg/dL) 14 263 ± 26 246 ± 19 *
Lipid peroxide (nmol/mL) 14 0.5 ± 0.4 0.4 ± 0.2
Twenty-three subjects with moderate hyperlipidemia (T-CHO level of >180
mg/dL or TG level of >150 mg/dL) before intake ingested Guava Leaf Tea (200
mL) with every meal for 8 weeks. Data were stratified by an initial serum T-
CHO level of >220 mg/dL. Values are expressed as mean ± SD. *: p < 0.05, #:
p = 0.06 (Dunnett’s multiple paired test). Reproduced from [33] with some
modifications.
Table 4 Effect of consecutive ingestion of Guava Leaf Tea
on serum adiponectin level in subjects with moderate
hyperlipidemia (stratified by the initial level of serum
adiponectin and HbA1c)
Serum adiponectin level (μg/mL)
n Initial week Week 8
Initial adiponectin level
< 4.0 μg/mL 5 2.3 ± 1.7 5.7 ± 1.8*
4.0 – 5.5 μg/mL 3 4.5 ± 0.7 4.9 ± 3.9
5.5 – 7.0 μg/mL 6 6.4 ± 0.4 6.8 ± 2.4
≧ 7.0 μg/mL 9 11.6 ± 4.8 13.0 ± 6.0
Initial HbA1c
≧ 6.5% 9 5.7 ± 1.8 6.8 ± 3.2*
< 6.5% 14 10.4 ± 5.3 5.7 ± 1.8
Subjects and conditions in the intervention are described in Table 3. Values
are expressed as mean ± SD. *: p < 0.05 (Dunnett’s multiple paired test).
Reproduced from [33] with some modifications.
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such as hypoglycemia or inhibition of drug activity.
Cytochrome P450 (CYP) isoforms in the human liver or
the small intestinal epithelium are known to be involved
in drug metabolism. Especially, CYP2C8, CYP2C9 and
CYP3A4, which are typical CYP isoforms, can metabo-
lize many commercial drugs. Grapefruit juice inhibits
CYP isoforms and shows abnormal interaction with
anti-diabetic drugs as well as many other commercial
drugs, such as repaglinide and tolbutamide (sulfony-
lurea) as a stimulator of insulin release from the pan-
creas, sibutramine as an appetite suppressant, HMG-
CoA reductase inhibitors, losartan as an angiotensin II
receptor antagonist, calcium channel blockers, and war-
farin [36,37]. Therefore, to evaluate the interaction
between Guava Leaf Tea and anti-diabetic and other
commercial drugs, Kaneko et al. [38] investigated the
inhibitory effects of GvEx and Guava Leaf Tea on
CYP2C8, CYP2C9 and CYP3A4 in vitro and compared
them with quercetin as another inhibitor and grapefruit
juice. Quercetin and grapefruit juice were shown to
have higher inhibitory effects on CYP2C8, CYP2C9 and
CYP3A4 than GvEx (more than 10-fold) and Guava Leaf
Tea (more than 2- to 10-fold), respectively. A subse-
quent histopathological study showed the absence of
response to the induction of P450 isoforms in the liver
of rats with 1-month repeated oral administration of
GvEx (2000 mg/kg/day). From these findings, it would
appear unlikely that Guava Leaf Tea can cause drug
interactions based on either inhibition or induction of
cytochrome P450 isoforms.
Deguchi et al. [39] investigated the effects of GvEx in
combination with typical alpha-GIs acarbose or vogli-
bose on alpha-amylase activity in vitro and postprandial
blood glucose elevation in mice. GvEx inhibited alpha-
amylase dose-dependently when combined with the low
active dose of acarbose or voglibose. When concomi-
tantly administered with acarbose or voglibose to nor-
mal mice, acarbose and voglibose each at the active
dose suppressed postprandial blood glucose elevation
following loading of sugars with no effect of GvEx (250
mg/kg). In contrast, at the inactive dose, acarbose and
voglibose did not affect the activity of GvEx (250 mg/
kg). Therefore, these findings indicate that the combined
ingestion of GvEx and an alpha-GI does not induce
hypoglycemia in an animal model.
To further examine the effects of drinking excessive
amounts of Guava Leaf Tea, human healthy subjects in
a previous study [31] ingested a 3-fold volume (600 ml)
of the tea. Notably, neither diarrhea nor hypoglycemia
was observed. Furthermore, single ingestion and the
consecutive ingestion of Guava Leaf Tea for 8 or 12
weeks with or without anti-diabetic and anti-
hyperlipidemia drugs in human clinical trials demon-
strated no side effects or abnormal changes, as described
earlier.
These findings indicate that Guava Leaf Tea and GvEx
induce neither toxicity, mutagenicity, nor abnormal
interaction with anti-diabetic and anti-hyperlipidemia
drugs, and have a lower potential for drug interactions
based on either inhibition or induction of cytochrome
P450 isoforms. Thus, Guava Leaf Tea and GvEx can be
deemed food and a safe food material, respectively.
6. Discussion
Acarbose [21,23] and voglibose [22,24] are each admi-
nistered as an oral hypoglycemic agent to improve post-
prandial hyperglycemia, fasting hyperglycemia and
hyperinsulinemia. In a previous non-insulin-dependent
diabetes mellitus trial (an international, multicenter,
double-blind, placebo-controlled trial) in which about
1,400 pre-diabetic subjects with impaired glucose toler-
ance were enrolled [40,41], it was demonstrated that
long-term treatment with acarbose decreases the risk of
T2DM, hypertension and cardiovascular disease. Also, a
recent randomized double-blind trial in Japan has pro-
ven that long-term treatment with voglibose reduces the
risk of progression to T2DM in about 1,800 pre-diabetic
subjects with impaired glucose tolerance [42]. It is
i m p o r t a n tt op o i n to u tt h a tt h ed e v e l o p m e n to fT 2 D M
is associated with the onset of cardiovascular disease.
Currently, there is ongoing debate as to whether post-
prandial blood glucose level is a stronger predictor of
cardiovascular events than fasting blood glucose in
T2DM [43,44]. Therefore, the adequate control of post-
prandial blood glucose level is highly important in pre-
venting the onset of T2DM or its complications in pre-
diabetic or diabetic patients. To prevent the develop-
ment of T2DM, pre-diabetic and non-diabetic subjects
are firstly managed by modification of lifestyle in order
to reduce body weight, without generally receiving phar-
macologic drug therapy which is considered for higher-
risk patients [45]. In this regard, both therapeutic exer-
cise and alimentotherapy are attractive alternatives and
recommended in both developed and developing coun-
tries. In Japan, FOSHU is particularly expected to aid in
the prevention of T2DM.
On further evaluations in animal models and a human
trial using subjects with or without pre-diabetes, a
reduction in postprandial blood glucose elevation has
been observed with a single oral ingestion of GvEx and
Guava Leaf Tea [15] (Figure 2). In addition, the
improvement of diabetes symptoms, such as hyperglyce-
mia, nephropathy (Table 1) and insulin resistance, has
been reported with the consecutive ingestion of GvEx in
diabetic animal models [15]. Moreover, some clinical
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of Guava Leaf Tea with every meal improved diabetes
symptoms and insulin resistance in pre-diabetic and dia-
betic patients [15,32] (Table 2). These observations indi-
cate that the chronic suppression of postprandial blood
glucose elevation, which is induced by the consecutive
ingestion of Guava Leaf Tea containing GvEx via its
alpha-glucosidase inhibition, plays an important role in
the improvement of not only hyperglycemia and dia-
betes symptoms, as similarly induced by typical alpha-
GIs, but also insulin resistance in pre-diabetic and dia-
betic patients.
A human study found that the consecutive ingestion
of Guava Leaf Tea with every meal improved hypoadi-
ponectinemia and hyperglycemia, showing an increase
in adiponectin level and a decrease in HbA1c% in blood
at each initial level [33] (Table 4). Recently, Ochiai et
al. [46] have demonstrated that treatment of T2DM
patients with acarbose for 12 weeks improves both
hypoadiponectinemia and hyperglycemia, showing an
increase in serum adiponectin level and a decrease in
HbA1c% in blood. These findings suggest that Guava
Leaf Tea has similar therapeutic potential to acarbose
for improving hypoadiponectinemia and hyperglycemia.
Moreover, there is a good inverse correlation between
adiponectin and HbA1c% in blood of the patients treated
with Guava Leaf Tea or acarbose. Although the exact
mechanism remains uncertain, the improvement of
hypoadiponectinemia and hyperglycemia is considered
to be associated with the chronic suppression of post-
prandial blood glucose elevation by alpha-glucosidase
inhibition.
A previous clinical trial has also demonstrated that the
consecutive ingestion of Guava Leaf Tea together with
every meal improved hypertriglyceridemia and hyperch-
olesterolemia [33] (Table 3). It is speculated that the
chronic suppression of postprandial blood glucose eleva-
tion is one of the underlying mechanisms involved in
the improvement of not only hyperglycemia and hypoa-
diponectinemia but also hypertriglyceridemia and
hypercholesterolemia. Hyperglycemia, hyperlipidemia
and hypercholesterolemia are some of the criteria indi-
cating metabolic syndrome and these conditions are clo-
sely associated with insulin resistance. It has been
hypothesized that an increase in adiponectin level in
hypoadiponectinemia improves insulin resistance,
T2DM and metabolic syndrome [5]. Taking the results
of all the clinical trials together, the consecutive inges-
tion of Guava Leaf Tea improves insulin resistance,
hyperlipidemia and hypercholesterolemia with or with-
out an increase in adiponectin level and a decrease in
HbA1c%. Such consecutive ingestion may be expected to
improve or prevent insulin resistance as well as meta-
bolic syndrome. To confirm efficacy and safety, further
large-scale clinical trials employing a larger number of
subjects with metabolic syndrome are warranted. In par-
ticular, the enrolment of patients who received anti-
hypertensive drugs and other commercial drugs is
important to obtain more information on the absence of
interaction between Guava Leaf Tea and these drugs.
In a crossover clinical trial of diabetic patients, it was
demonstrated that Guava Leaf Tea has a milder redu-
cing activity for postprandial glucose elevation than
voglibose, a typical alpha GI. This is based on the lower
activity of GvEx on sugar-degrading enzymes than vogli-
bose. However, alpha-GIs have been reported to have
side effects, such as diarrhea, meteorism, flatulence and
abdominal wind [14,23,47]. One mechanism suggested
to underlie these side effects is that the potent inhibition
of sugar-degrading enzymes allows undigested sugars to
reach the colon where they stimulate the abnormal pro-
duction of several acids by intestinal bacteria. This is
followed by a decrease in intestinal pH and the genera-
tion of carbon dioxide gas, which are responsible for the
side effects. In contrast and as described earlier, no
abdominal symptoms were observed after the consecu-
t i v ei n g e s t i o no fG u a v aL e a fT e af o r8o r1 2w e e k si n
some human trials. In addition, previous in vitro studies
and investigations using animal models have demon-
strated that Guava Leaf Tea and GvEx induce neither
toxicity nor mutagenicity. Moreover, both GvEx and
Guava Leaf Tea have weak inhibitory activity on cyto-
chrome P450 isoforms, which are associated with the
metabolism of anti-diabetic drugs and many commercial
drugs. This suggests that Guava Leaf Tea has a lower
potential for abnormal interaction with these drugs. It is
therefore suggested that Guava Leaf Tea containing
GvEx is a useful and harmless food for treating pre-dia-
betic and diabetic patients.
Conclusions
On the basis of numerous lines of scientific evidence
regarding the effectiveness and safety of Guava Leaf Tea
containing GvEx for treating T2DM, it was approved as
FOSHU in March 2000 and it is recommended for indi-
viduals who are anxious about their high blood glucose
and control of sugar uptake. Many Japanese consumers
have taken the commercially available tea and are likely
to maintain good health. The consecutive ingestion of
Guava Leaf Tea with every meal is expected to benefit
pre-diabetic and diabetic patients as an alimentotherapy
in both developed and developing countries.
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